Clinical expertise in choosing and managing drug therapy for schizophrenia for an individual patient involves an understanding of the research evidence concerning the efficacy, effectiveness, and efficiency of the options, balanced with consideration of the patient’s clinical circumstances, and their preferences and attitudes. These guidelines can support the implementation of evidence-based research findings into clinical practice by improving such understanding, specifically, providing an up-to-date summary of evidence regarding the benefits and risks of pharmacological interventions and highlighting areas of current uncertainty. The At-risk mental state: Encourage a therapeutic relationship to allow for further assessment, review, ‘watchful waiting’ and monitoring of symptoms.
Assess the nature and impact of any substance use. Substance use in this group is not common and rarely…
